Slide 1: Q4 & FY25
• Mankind//JJJ,,,. J~$gle, Q4 & FY25 May, 2025
Slide 2: Index
~ Mankind/I/JI,. J~.t',# Index 03 Additional Information • Mankind Pharma at a Glance • Key Milestones • BSV at a Glance • Expansion in Specialty and Super Specialty 01 Financial Performance Segments • Key Financials – Q4 FY25 • Key Strengths • P & L Highlights – Q4 & FY25 • Strategy Going Ahead • K
Slide 3: Financial Performance
• Mankind//JJJ,,,. J~$gle, i I ■ I rf rm n
Slide 4: Q4 FY25 - Key Financial Snapshot
Q4 FY251 - Key Financial Snapshot Financials / Margins Growth Capital Efficiency • Mankind//JJJ,,,. J~~ge, 3,079 27.1% 11% / 40% Revenue (INR Cr) YoY Growth ROCE / Adj. ROCE3 686 / 22.3% 16.4% 5,784 EBITDA (INR Cr) / Margin YoY Growth Net Debt (INR Cr) 711 / 23.1% 20.7% 1.8x Adj. EBITDA2 / Margin Yo
Slide 5: Q4 & FY25 - P&L Highlights
Q4 & FY251 - P&L Highlights YoY QoQ YoY • Mankind//JJJ,,,. J~~ge, INR Cr Q4FY25 Q4FY24 Q3FY25 FY25 FY24 Growth Growth Growth Revenue from Operations 3,079 2,422 27.1% 3,199 -3.7% 12,207 10,260 19.0% (A=B+C) Domestic Business (B) 2,544 2,155 18.1% 2,742 -7.2% 10,675 9,447 13.0% i. Domestic Business (
Slide 6: Key Financial Metrics
Key Financial Metrics1 Cash Flow from Operations (INR Cr) CAPEX (INR Cr) ROCE2 • Mankind//JJJ,,,. J~~ge, CFO to CAPEX as 95% 84% 80% 9.5% 3.8% 4.3% EBITDA % of Rev With BSV 832 Acquisition 2,413 134 1,813 2,152 40% 221 531 34% 516 814 484 389 187 25% 667 460 65 611 360 99 91 481 593 114 128 879 488
Slide 7: Business Updates
• Mankind/II• Jerot&~ge, ■ I t
Slide 8: Domestic Business Performance
Domestic Business Performance Strong Growth in Domestic Revenue1,2 • Mankind//JJJ,,,. J~~ge, INR Cr ___ 11% 12% __,...-- - - - · - 9,447 13% .. 10,675 8,453 7,595 18% ~ - - 2,155 2,544 FY22 FY23 FY24 FY25 Q4FY24 Q4FY25 Market share has Increased from 4.4% in Mar-24 to 4.8%3 as of Mar-25 on account
Slide 9: BSV and chronic share
Increased chronic share by 150 bps* in FY25 • Mankind//JJJ,,,. Consistent focus to increase chronic contribution + BSV bringing life to life BSV’s super specialty portfolio - ,----------------------, : 1 I ~ Mankind!!/► Se,v""a'Li[e, Mankind Consolidated BSV ~"""''"'"'"' : 1 I 38.3 39.0 39.7 40.2 40
Slide 10: Q4FY25 - Therapy wise Performance
Q4FY25 – Therapy wise Performance • Mankind//JJJ,,,. J ~ ~ge, 1 High Ranks across Acute and Chronic Areas Q4FY25 - Sales Mix representing Diversified Therapy Presence Rank in FY 21-25 CAGR 2% MS% Key Therapy Areas CVM 10% (Q4FY25) 16% (Q4FY25) Mankind IPM 4% • Cardiovascular • Anti-Infectives Chroni
Slide 11: FY25 Business Update
FY25 Business Update • Mankind//JJJ,,,. 1 J~~ge, Performance vs IPM 1.2x outperformance to IPM chronic in FY25 7.6% 8.5% 8.0% 7.5% 38% 36% 39% 37% 13.5 3.2% 2.3% 11.9 3.0% 2.8% 9.8 9.7 5.8% 4.3% 4.0% 4.2% 0.7% -0.6% 1.4% 0.5% IPM Mankind IPM Mankind FY24 FY24 FY25 FY25 FY24 FY25 ■ Volume ■ Price ■ N
Slide 12: Consistently Built and Scaled Brands
Consistently Built and Scaled Brands • Mankind//JJJ,,,. J~~ge, CAGR Key Brands1 >INR 500 Cr Brand Families FY 21 FY 25 (FY21-25) > INR 500 Crore 0 3 15% ... •·l-Camitine l-Tartrate, Mecobala;;;- &Folic Acid Tablets " mMIIARIAN &HYDROCHLOROIHW!Df IABlflS IP -· NUROKIND'· LC > INR 200 Crore 7 11 14% T
Slide 13: Building Consumer Healthcare Franchise
Building Consumer Healthcare Franchise Consumer Healthcare Segment Revenue (INR Cr) • Mankind//JJJ,,,. J~~ge, EBITDA % 19.9% 19.0% 20.6% 20.1% 809 692 706 589 14% - 156 178 FY22 FY23 FY24 FY25 Q4FY24 Q4FY25 Strong revenue growth of 14% YoY in Q4FY25 led by steady growth across all key brands Rev
Slide 14: Strong Corporate Identity Complements Brand Recall
Strong Corporate Identity Complements Brand Recall… Strategically selected national and regional brand ambassadors • Mankind//JJJ,,,. J~~ge, Corporate Brand Ambassadors Dominant Brands Consumer Healthcare Brand Ambassadors #1 MAN~ Condom Brand Kartik Aaryan .,._ Sunny Leone Radhika Apte Market Share
Slide 15: With Targeted Marketing Initiatives
…With Targeted Marketing Initiatives Digital campaigns around April Fool's Built a WhatsApp community Women’s Day campaign hit Print ads in key north 70M+ views, 2L+ shares, and day with Dot AI, with 43.3M+ Views “Prega Squad” for moms to and west market 55L+ likes 334K+ shares foster open communica
Slide 16: Exports Business Update
Exports Business Update Revenue from Exports (INR Cr) 1,532 813 535 296 267 187 FY22 FY23 FY24 FY25 Q4FY24 Q4FY25 Revenue growth of 100% YoY driven by increase in our base business supported by new launches in last 12-24 months and consolidation of BSV Mankind (excl. BSV) has launched 1 product
Slide 17: Additional Information
• Mankind//JJJ,,,. J~$gle, ■ I
Slide 18: Mankind Pharma at a Glance - FY25
Mankind Pharma at a Glance - FY251 #1 #2 #4 4 Rank in Prescriptions over Rank by volume in Rank by value in Consumer Healthcare brands Market the last eight years2 IPM2 IPM2 ranked #1 in their categories2 Leadership INR 12,207 Cr 87% 49/23 18,000+ Brand families2 worth FY25 Revenue FY25 Domestic Rev
Slide 19: Key Milestones - Disruption led growth
Key Milestones – Disruption led growth 1995 2004 2007-10 2018-19 2020-21 2022 2023 2024 Entered into in- Acquired 100% stake in licensing agreements BSV Limited Successfully listed Commenced Entered chronic Entered Paonta Sahib Launched dedicated specialty Acquired brands with: on NSE and BSE operat
Slide 20: BSV at a Glance
BSV at a Glance Focused Therapy Presence Differentiated Tech Platforms FY 25 Sales Mix International India 49% 51% Women’s Fertility Critical Recombinant Tech Complex Immunoglobulins Health Care and Niche Biologics Delivery Systems Key Initiatives Recombinant Liposomal Anti-thymocyte Domestic WH Rx
Slide 21: Consistently Expanding to Specialty and Super Specialty
Consistently Expanding to Specialty and Super Specialty Mass Market Specialty Chronic (Acute/ Chronic / Semi Chronic) (Cardio / Diabeto / CNS) Consumer Healthcare (OTC) BSV - Super Specialty Targeted Medical Practitioners Targeted Medical Practitioners Targeted Medical Practitioners GP CP MD MD DM K
Slide 22: Key Strengths
Key Strengths India revenues contribute 87% of total revenues in FY251 Focus on Focus on Consistent CFO/ EBITDA ratio of ~80% domestic domestic during FY25 business Volume- Best in class business cash growth driven #2 rank by volume in IPM2 conversion by metrics 1 affordability 9 2 Strong 75% of man
Slide 23: Strategy Going Ahead
Strategy Going Ahead Consolidate market share in increased CVM - Deeper penetration in incremental CVM (62% in FY21 to 72% in FY25) driven by volume focused growth and scaling up brands. Increasing chronic share - Increasing presence in chronic therapies (Diabetes – Empagliflozin, and Insulin Glargi
Slide 24: Consistently Expanding Our Portfolio Towards Specialty Products
Consistently Expanding Our Portfolio Towards Specialty Products Reference Market Brand Launched Market 5 Therapy Area Indication Size Rationale (Year) (INR Cr) – FY25 Year CAGR # (FY22) • Neptaz – In-licensed from Novartis. Strong Revenue and Volume Heart Failure 7251 19% growth. Ranks in the top 5
Slide 25: Financials - Steady Growth Trajectory
1 Financials - Steady Growth Trajectory Revenue (INR Cr) Strong Growth in Domestic Revenue Revenue from Exports (INR Cr) 18% 15% CAGR CAGR 69% 12,207 CAGR 10,260 10,675 1,532 8,749 9,447 7,782 8,453 7,595 6,214 6,028 813 296 186 187 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY
Slide 26: Key Performance Highlights
Key Performance Highlights Key Performance Highlights FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 Value Growth YoY in IPM (%) 11.3 12.6 12.5 11.1 17.7 10.6 8.5 7.5 Market share by Value in IPM (%) 3.9 4.0 4.1 4.3 4.3 4.4 4.4 4.8 Market Ranking by Value in IPM (x) 4 4 4 4 4 4 4 4 CVM share in total IPM (
Slide 27: ESG: Organization Focus on Sustainable Growth FY25
ESG : Organization Focus on Sustainable Growth FY25 Key Key Key Adoption of Highlights Initiatives Priorities Technologies Zero Reportable Lost Time accidents across all manufacturing units • International Safety Award • Five-Star Rating' from the • 5 star safety assessment at • Highly Hazardous rea
Slide 28: Mankind's Sustainability goals
Mankind’s Sustainability goals Focus Area Goals* Status FY25 Occupational Health & Safety ZERO Lost Time Accidents No Lost Time Accident in FY25 Achieved as per Extended Producer Plastic Neutral 100% by FY24 Responsibility requirements Carbon Neutral Achieved 66% reduction in FY25 from 100% by FY30
Slide 29: Shareholding Pattern
Shareholding Pattern BSE Ticker 543904 1.6% 4.0% 7.7% NSE Symbol MANKIND 14.0% # of Shares outstanding* 41,25,78,527 Share Price* 2,424.75 Market Cap. (INR Crore)* 1,00,040 72.7% % Free Float 27.3 Free Float Market Cap. (INR Crore) 27,311 Promoters FPI & Bodies Corporate Mutual Funds Retail Others I
Slide 30: Annexures
~ □ Annexures Mankind/1/JJ,,,. J'~$tfo • ROCE = (EBIT for the year ) / (Capital employed less cash) o EBIT excludes other income o Capital employed is the sum of total equity, total borrowings, total lease liabilities and deferred tax liabilities (net) less deferred tax assets and Cash. • Adjusted R
Slide 31: Q4 & FY25 - P&L Highlights
1 Q4 & FY25 – P&L Highlights YoY QoQ YoY INR Cr Q4FY25 Q4FY24 Q3FY25 FY25 FY24 Growth Growth Growth Revenue from Operations 3,083 2,441 26.3% 3,230 -4.5% 12,283 10,335 18.8% (A=B+C) Domestic Business (B) 2,548 2,174 17.2% 2,773 -8.1% 10,751 9,522 12.9% i. Domestic Business (ex CH) 2,370 2,018 17.5%
Slide 32: Safe Harbour Statement
~ □ Safe Harbour Statement Mankind/1/JJ,,,. J'~$tfo The statements, are as on date and may contain forward-looking statements like the words “believe”, “expects”, “anticipate”, “aim”, “will likely result”, “would”, “will continue”, “contemplate” “intends”, “plans”, “estimates”, “seek to”, “future”,
Slide 33: Q4 & FY25 Earnings Call Details
Q4 & FY25 Earnings Call Details Date 21st May, 2025 Time 18:00 IST Dial – in Details Universal Access Numbers +91 22 6280 1102 / +91 22 7115 8003 https://services.choruscall.in/DiamondPassRegistration/register?confirm Diamond Pass ationNumber=7466277&linkSecurityString=352b15497d 33
Slide 34: Thank You
Thank You For more information please visit our website: https://www.mankindpharma.com For specific queries, contact: Abhishek Agarwal Head - Investor Relations 011 – 46846700 Ext. 3532 Investor.relations@mankindpharma.com